A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
Hui YangShaoxing SunZijie MeiQingming XiangChunxu YangMin ChenConghua XieYunfeng ZhouHui QiuPublished in: Drug design, development and therapy (2021)
Anlotinib showed beneficial efficacy and safety and can be a treatment option for patients with persistent, metastatic, or recurrent cervical cancer who have failed the first-line therapy.